Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

CANCER-RADIOMICS

Financiado

Deep Learning for Automated Quantification of Radiographic Tumor Phenotypes

Artificial Intelligence (AI), deep-learning in particular, is propelling the field of radiology forward at a rapid pace. In oncology, AI can characterize the radiomic phenotype of the entire tumor and provide a non-invasive window... ver más

31/07/2025

UNIVERSITEIT MAAST...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-07-03

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100%

2 Participantes

UNIVERSITEIT MAASTRICHT

2.00M€ | Lider

LTO SYSTEMS

373.72K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2020-07-03
Fecha Fin: 2025-07-31

Líder del proyecto

UNIVERSITEIT MAASTRICHT

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Artificial Intelligence (AI), deep-learning in particular, is propelling the field of radiology forward at a rapid pace. In oncology, AI can characterize the radiomic phenotype of the entire tumor and provide a non-invasive window into the internal growth patterns of a cancer lesion. This is especially important for patients treated with immunotherapy as, despite the remarkable success of these novel therapies, the clinical benefit remains limited to a subset. As immunotherapy is expensive and could bring unnecessary toxicity there is a direct need to identify beneficial patients, but this remains difficult in clinical practice today. Radiomic biomarkers could address this, as, unlike biopsies that only represent a sample within the tumor, radiomics can depict a full picture of each cancer lesion with a single non-invasive examination. Previous work found significant connections between radiomic data, molecular pathways, and clinical outcomes. However, a direct link between radiomics and immunotherapy response has not yet been established. This project will address this problem by analyzing unique multicentre clinical data, including non-invasive imaging, clinical outcomes, and extensive biologic characterization of patients with lung or melanoma cancer. Specifically, I will develop deep-learning radiomic biomarkers to predict immunotherapy response using baseline (WP1) and follow-up imaging (WP2). I will also investigate if radiomics can characterize underlying biological factors, and, in turn, can be used to improve response predictions (WP3). Successful completion of this proposal will demonstrate the potential of radiomics to help physicians in selecting patients who will likely benefit from immunotherapy, while sparing this expensive and potentially toxic treatment for patients who don't. This work has implications for the use of imaging-based biomarkers in the clinic, as they can be applied noninvasively, repeatedly, and at low additional cost.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores